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Abstract
Background: The idea that the impact of opioid agonist treatment is influenced by the psychopathological profile
of heroin addicts has not yet been investigated, and is based on the concept of a specific therapeutic action
displayed by opioid agents on psychopathological symptoms. In the present report we compared the effects of
buprenorphine and methadone on the psychopathological symptoms of 213 patients (106 on buprenorphine and
107 on methadone) in a follow-up study lasting 12 months.
Methods: Drug addiction history was collected by means of the Drug Addiction History Rating Scale (DAH-RS) and
psychopathological features were collected by means of the Symptom Checklist-90 (SCL-90), using a special five-
factor solution. Toxicological urinalyses were carried out for each patient during the treatment period.
Results: No statistically significant differences were detected in psychopathological symptoms, including
‘worthlessness-being trapped’, ‘somatization’, and ‘panic-anxiety’. Methadone proved to be more effective on
patients characterized by ‘sensitivity-psychoticism’, whereas buprenorphine was more effective on patients
displaying a ‘violence-suicide’ symptomatology.
Conclusions: Heroin-dependent patients with psychiatric comorbidities may benefit from opioid agonist treatment
not only because it targets their addictive problem, but also, precisely due to this, because it is effective against
their mental disorder too.
Background
While psychiatric comorbidity has been shown to have a
negative impact on the outcome of opioid use disorders
[1-9], studies carried out in the context of Methadone
Maintenance Treatment Programs (MMTPs) to evaluate
outcomes strictly linked with methadone efficacy have
not demonstrated any such negative influence [10-14].
The complex nature of psychopathology in substance
abuse disorders (SUDs), is particularly difficult to assess
at the moment of admission to treatment, when the het-
erogeneity of the psychological/psychiatric conditions
displayed impairs the attribution of symptoms to psy-
chiatric conditions preceding the initial use of
substances, to the effects of heroin and/or other sub-
stances, to neurobiological addictive processes, or to
psychosocial stress associated with addictive behavior
[15-18]. On these bases a unitary perspective has been
proposed, foreseeing the inclusion of symptoms of anxi-
ety, mood and impulse-control domains in the psycho-
pathology of addiction, but also taking into account
symptoms and syndromes that are under the threshold
for the definition of an additional mental disorder,
although they may have a strong effect on the everyday
life of patients and may frequently require intervention
[19,20].
This approach is consistent with the often-found ten-
dency in the field of addiction to evaluate the impact of
psychopathology on the outcome of a treatment in
terms of the severity of the psychological/psychiatric
problems involved through the use of rating scales and
* Correspondence: maremman@med.unipi.it
1’Vincent P. Dole’ Dual Diagnosis Unit, Santa Chiara University Hospital,
Department of Psychiatry, NPB, University of Pisa, Pisa, Italy
Full list of author information is available at the end of the article
Maremmani et al. Annals of General Psychiatry 2011, 10:17
http://www.annals-general-psychiatry.com/content/10/1/17
© 2011 Maremmani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.interviews such as the Symptom Checklist-90 (SCL-90)
and Anxiety Sensitivity Index (ASI), rather than in
terms of formal psychiatric diagnoses [21-25].
Recently, using the SCL-90, we studied the psycho-
pathological dimensions of 1,055 patients with heroin
addiction (884 males and 171 females) aged between 16
and 59 years at the beginning of treatment, and their
relationship to age, sex and duration of dependence. We
found five subgroups of patients characterized by (1)
depressive symptomatology with prominent feelings of
worthlessness-being trapped or caught, (2) somatization
symptoms, (3) interpersonal sensitivity and psychotic
symptoms, (4) panic symptomatology, and (5) violence
and self-aggression. These groups were not correlated
with sex or duration of dependence. Younger patients
with heroin addiction were more strongly represented in
prominent violence-suicide, sensitivity and panic-anxiety
symptomatology groups. Older patients were more
strongly represented in prominent somatization and
worthlessness-being trapped symptomatology groups
[26].
Therefore, we wondered if methadone and buprenor-
phine have the same impact on the psychopathological
dimensions mentioned above.
In a previous study we evaluated the efficacy of bupre-
norphine and methadone on psychopathological symp-
toms according to a standard SCL-90 nine-factor
structure [27]. We treated 213 patients (106 of these on
buprenorphine and 107 on methadone) in an open
study, following patients between months 3-12 of their
treatment; those who left the program before the end of
their third month of treatment were excluded from the
study sample. The results of this study showed statisti-
cally significant improvements in opioid use, psychiatric
symptomatology and quality of life between months 3-
12 for both medications [24].
In the present study we compared the effects of
buprenorphine and methadone on the psychopathologi-
cal symptoms of these same patients after re-evaluation
on the basis of our new five-factor SCL-90 structure.
Methods
Sample
The sample comprised 213 heroin-dependent patients
selected according to Diagnostic and Statistical Manual
of Mental Disorders, 4th edition, text revision (DSM-IV-
TR) criteria [28]: their mean age was 31 (SD 6), 176
(82.6%) were males, 130 (61.0%) were single, 135
(63.4%) had a low educational level (≤8 years), 81 (38%)
were unemployed and 6 (2.8%) were receiving welfare
benefits. In all, 106 patients were being treated with
buprenorphine and 107 with methadone. For further
details, please see Maremmani et al. [24].
On the basis of the highest z scores obtained on the
five SCL-90 factors (dominant SCL-90 factor) (see
Instruments section below) subjects were assigned to
five mutually exclusive groups. Six subjects (2.8%) had
missing data. The group whose dominant factor was
‘worthlessness-being trapped’ comprised 33 subjects
(15.6%), the group with ‘somatization’ as its dominant
factor was made up of 43 subjects (20.3%), the group
showing ‘sensitivity-psychoticism’ as its dominant factor
included 31 subjects (14.6%), the group identified by
‘panic-anxiety’ as its dominant factor numbered 66 sub-
jects (30.3%), and the group whose dominant factor was
‘violence-suicide’ profiled a cluster of 39 subjects
(17.9%). These five groups were sufficiently distinct, and
did not show any significant overlap. All these patients
showed positive scores in their dominant factors only,
alongside negative scores in all the others; the only
exception being a small number of patients whose
dominant factor was ‘worthlessness-being trapped’,w h o
recorded a positive score for the ‘sensitivity psychoti-
cism’ factor (mean ± SD = 0.06 ± 0.5) This finding was
confirmed by the discriminant analysis, which indicated
a percentage of correctly classified ‘grouped’ cases as
high as 90.1%.
Instruments
Drug Addiction History Rating Scale (DAH-RS)
The DAH-RS [29] is a multiscale questionnaire compris-
ing the following categories: sociodemographic informa-
tion, physical health, mental health, substances abused,
treatment history, social adjustment and environmental
factors. The questionnaire rates ten items: physical pro-
blems, mental problems, substance abuse, previous
treatment, associated treatments, employment status,
family situation, sexual problems, socialization and lei-
sure time, legal problems. (The specific clinical variables
addressed are: hepatic, vascular, hemolymphatic, gastro-
intestinal, sexual, dental pathology, HIV serum status,
memory disorders, anxiety disorders, mood disorders,
aggressiveness, thought disorders, perception disorders,
awareness of illness; employment, family, sex, socializa-
tion and leisure time, legal problems; use of alcohol,
opiates, central nervous system (CNS) depressants, CNS
stimulants, hallucinogens, phencyclidine, cannabis, inha-
lants, polysubstance abuse, frequency of drug use, pat-
tern of use, previous treatments and current
treatments). Items are constructed in order to obtain
dichotomous answers (yes/no).
SCL-90
The SCL-90 [27] is an inventory composed of 90 items,
with a point scale ranging from 0 to 5, to allow assess-
ment of intensity. The items are grouped into five
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sions: worthlessness-being trapped, somatization, sensi-
tivity-psychoticism, panic-anxiety and violence-suicide.
The five-factor solution is based on an exploratory fac-
tor analysis we performed on the 90 SCL items. This
analysis involved 1,055 patients [26]. The ratio of
patients/items (11:1) was high enough to authorize this
analysis, as it is higher than the recommended 10:1
ratio. Factors were extracted by using a main compo-
nent analysis (principal component analysis (PCA) type
2) and then rotating this orthogonally to achieve a sim-
ple structure. This simplification is equivalent to maxi-
mizing the variance of the squared loading in each
column. To limit the factor number, the criterion used
was an eigenvalue >1.5. Items loading with absolute
values >0.40 were used to describe the factors. This pro-
cedure makes it possible to minimize the crossloadings
of items on factors. In order to make factor scores com-
parable, they can be standardized into z scores. All sub-
jects can be assigned to one of the five different
subtypes on the basis of the highest factor score
achieved (dominant SCL-90 factor). This procedure
allows the classification of subjects on the basis of their
dominant symptomatological cluster. In this way it is
possible to solve the problem of identifying a cut-off
point for the inclusion of patients in the different clus-
ters identified.
Urinalysis
The toxicological urinalyses were expressed using two
indices, PCC (PerCent ‘Clean’) and TEC (out of Total
Executed percent ‘Clean’). PCC expresses the percentage
ratio of urinalyses proving negative for the presence of
morphine and the total number of urinalyses carried out
for each patient during the period of treatment. TEC is
the percentage ratio between the number of urinalyses
that proved to be negative for the presence of morphine
and the number of urine analyses that the protocol has
envisaged throughout the process. In this case, the refer-
ence number was 37 (the maximum number of urine
samples per patient). PCC tends to give preference to
patients who remain ‘opiate free’, but who terminate the
study in advance for reasons not correlated with the
study (for example, imprisonment). TEC additionally
considers how long the patient remains in the protocol,
and gives less precedence to these patients. These two
indices represent the two extremes, but results tend to
balance out. With regard to these parameters, the com-
parison between the two groups was made with Stu-
dent’s t test.
Data analysis
Analysis of the results was performed on completion of
the 12 months of treatment. Patients belonging to one
of the five dominant subgroups and undergoing treat-
ment, with buprenorphine or with methadone, were
compared for their retention in treatment. Retention in
treatment was analyzed by means of survival analysis
and Leu-Desu statistics for comparison between the sur-
vival curves. For the purpose of this analysis, ‘completed
observations’ is a term that refers to patients who left
the treatment, while ‘censored observations’ refers to
patients who are still in treatment at the end of the 12
month period or have decided to leave the treatment for
reasons unrelated to treatment (for example, patients
moving to other towns, imprisonment, and so on). The
homogeneity of the population samples treated with
buprenorphine or methadone according to SCL-domi-
nant groups was tested by means of Student’s t test for
continuous variables and c
2 test for categorical variables.
We used the statistical routines in SPSS V.4.0 (SPSS,
Chicago, IL, USA).
Results
At 12 months (Table 1) no statistically significant differ-
ence was observed regarding subjects belonging to the
‘worthlessness-being trapped’ dominant group and trea-
ted with methadone or buprenorphine. Similarly, no sta-
tistically significant differences were observed for
patients belonging to the ‘somatization’, and ‘panic-anxi-
ety’ dominant groups.
Table 1 Survival in treatment of buprenorphine-treated
or methadone-treated heroin-dependent patients
according to dominant psychopathological groups
N CEN* % P value
Independently of psychopathology
Buprenorphine 108 88 81.48
Methadone 104 84 80.77 0.94
Worthlessness-being trapped
Buprenorphine 18 14 77.78
Methadone 15 9 60.00 0.39
Somatization
Buprenorphine 24 20 83.33
Methadone 19 17 89.47 0.58
Sensitivity-psychoticism
Buprenorphine 15 8 53.33
Methadone 16 14 87.50 0.03
Panic-anxiety
Buprenorphine 29 25 86.21
Methadone 37 32 86.49 0.98
Violence-suicide
Buprenorphine 19 19 100.00
Methadone 20 14 70.00 0.01
* censored
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14 (87.5%) out of 16 patients in treatment with methadone
were still in treatment. During the same period, only 8
(53.3%) out of 15 patients in treatment with buprenor-
phine were still in treatment. This difference was statisti-
cally significant. Patients treated with buprenorphine or
methadone did not differ significantly in rates for gender,
education, civil status, presence of somatic comorbidity,
psychiatric comorbidity, baseline household major pro-
blems, sexual major problems, social-leisure major pro-
blems, legal problems or polyabuse. No significant
differences were observed either in age, age at first use of
substances, age at dependence onset, dependence duration
or age at first treatment. During the follow-up period no
statistically significant differences were observed regarding
urinalyses for heroin or cocaine metabolites. More unem-
ployed patients with work major problems and with past
unsuccessful treatments were present in the methadone
group (see Table 2).
Considering the ‘violence-suicide’ dominant group, all
(n = 19) patients treated with buprenorphine were still
in treatment. During the same period, 14 (70.0%) out of
20 patients in treatment with methadone were still in
treatment. This difference was statistically significant.
Patients treated with buprenorphine or methadone did
not differ significantly in rates of employment, educa-
tion, civil status, presence of somatic comorbidity, psy-
chiatric comorbidity, baseline work major problems,
household major problems, sexual major problems, legal
problems, polyabuse or unsuccessful treatments in the
past. No significant differences were observed either in
age, age at first use of substances, age at dependence
onset, dependence duration, age at first treatment. Dur-
ing the follow-up period no statistically significant
Table 2 Demographic and clinical characteristics of the sensitivity-psychoticism dominant groups according to
treatment
Buprenorphine (N = 15) Methadone, (N = 16) P value
N (%) N (%) c
2
Gender (males) 13 (86.7) 14 (87.5) 0.00 0.944
Work: 7.72 0.052
Student 0 (0.0) 1 (6.3)
Blue collar 2 (20.0) 3 (18.8)
White collar 11 (73.3) 5 (31.3)
Unemployed 1 (6.7) 7 (43.8)
Education: >8 years 4 (26.7) 5 (31.3) 0.07 0.778
Civil status: single 13 (86.7) 12 (75.0) 0.67 0.411
Somatic comorbidity 10 (66.7) 13 (81.3) 0.85 0.350
Psychiatric comorbidity 10 (66.7) 14 (93.3) 3.33 0.060
Work major problems 0 (0.0) 7 (46.7) 9.1 0.002
Household major problems 14 (93.3) 13 (81.3) 1.00 0.315
Sexual major problems 12 (80.0) 13 (81.3) 0.00 0.929
Social-leisure major problems 11 (73.3) 12 (75.0) 0.01 0.915
Legal problems 2 (13.3) 6 (37.3) 2.36 0.124
Polyabuse 9 (60.0) 10 (62.5) 0.02 0.886
Past unsuccessful treatments 8 (53.3) 16 (100.0) 9.64 0.001
Mean ± SD Mean ± SD T*
Age 27 ± 5 30 ± 4 -1.90 0.067
Age at first use, years 18 ± 5 19 ± 5 -0.75 0.463
Age at dependence onset, years 20 ± 5 23 ± 5 -1.09 0.284
Dependence duration, months 53 ± 40 75 ± 46 -1.36 0.186
Age at first treatment, years 22 ± 5 25 ± 4 -1.54 0.136
Heroin PCC 89.16 ± 27.5 83.96 ± 17.9 0.62 0.542
Heroin TEC 21.84 ± 13.9 25.59 ± 15.4 -0.70 0.490
Cocaine PCC 94.16 ± 13.3 85.83 ± 16.3 1.56 0.130
Cocaine TEC 22.88 ± 12.6 23.60 ± 16.5 -0.12 0.902
* Student T-test; PCC = Percent ‘clean’; TEC = Total Executed ‘Clean’
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oin or cocaine metabolites. More males and patients
with social-leisure major problems were present in the
buprenorphine group (see Table 3).
Discussion
In our sample, the question of whether a patient
belonged to one of the ‘worthlessness-being trapped’,
‘somatization’ and ‘panic-anxiety’ dominant groups did
not affect survival in treatment. Patients with ‘sensitiv-
ity-psychoticism’ as their predominant characteristics
showed a better outcome when treated with methadone.
Patients with ‘violence-suicide’ as their predominant
characteristics showed a better outcome when treated
with buprenorphine. This occurred despite the fact that
methadone-treated sensitivity-psychoticism patients
showed a higher frequency of unemployment, of work
major problems and of unsuccessful treatments in the
past compared with patients possessing the same predo-
minant characteristics who were treated with buprenor-
phine. Buprenorphine-treated violence-suicide patients
were characterized by the male gender and showed a
better outcome, despite the presence of social-leisure
major problems. In our sample methadone and bupre-
norphine showed the same effect on heroin dependence
(as proved by results for urinalyses that were not statis-
tically different), but did show a different impact on psy-
chopathology when patients were assessed using our
new five-factor SCL-90 solution.
The impact of long-acting opioid treatment on the
psychopathological profile of heroin addicts has not yet
been fully investigated, despite the possibility (reported
in the literature) that opioid agents have a specific ther-
apeutic action on psychopathological symptoms.
In the literature, opioid agents have been reported to
h a v eat h e r a p e u t i ce f f e c ti naw i d er a n g eo f
Table 3 Demographic and clinical characteristics of the violence-suicide dominant groups according to treatment
Buprenorphine (N = 19) Methadone, (N = 20) P value
N (%) N (%) c
2
Gender (males) 18 (94.7) 12 (60.0) 6.62 0.01
Work: 3.56 0.313
Student 3 (15.8) 0 (0.0)
Blue collar 4 (21.1) 4 (20.0)
White collar 7 (36.8) 9 (45.0)
Unemployed 5 (26.3) 7 (35.0)
Education: >8 years 8 (42.1) 11 (55.0) 0.64 0.42
Civil status: single 11 (57.9) 9 (45.0) 0.64 0.42
Somatic comorbidity 11 (57.9) 12 (60.0) 0.01 0.893
Psychiatric comorbidity 14 (77.8) 16 (84.2) 0.24 0.617
Work major problems 5 (26.3) 8 (42.1) 1.05 0.304
Household major problems 17 (89.5) 17 (89.5) 0 1
Sexual major problems 17 (89.5) 17 (94.4) 0.3 0.579
Social-leisure major problems 16 (84.2) 8 (42.1) 7.23 0.007
Legal problems 7 (36.8) 7 (35.0) 0.01 0.904
Polyabuse 11 (57.9) 15 (75.0) 1.28 0.257
Past unsuccessful treatments 14 (73.7) 18 (90.0) 1.76 0.184
Mean ± SD Mean ± SD T*
Age 28 ± 7 30 ± 6 -1.13 0.264
Age at first use, years 16 ± 2 18 ± 4 -1.79 0.082
Age at dependence onset, years 18 ± 2 20 ± 4 -1.62 0.116
Dependence duration, months 81 ± 67 124 ± 94 -1.63 0.112
Age at first treatment, years 21 ± 3 24 ± 4 -1.91 0.065
Heroin PCC 92.74 ± 10.7 80.52 ± 27.7 1.83 0.079
Heroin TEC 30.60 ± 19.2 30.58 ± 27.7 0 0.998
Cocaine PCC 87.23 ± 24.8 86.62 ± 19.6 0.08 0.933
Cocaine TEC 30.38 ± 24.3 34.06 ± 29.4 -0.4 0.691
* Student T-test; PCC = Percent ‘clean’; TEC = Total Executed ‘Clean’
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the fact that dual diagnosis heroin addicts need higher
stabilization dosages (150 mg/day on average) than
those without any additional psychiatric disorder (whose
average dose is 100 mg/day) [11].
With regard to mood disorders, opiates were used to
treat major depression until the 1950s. More recently,
consistently with the endorphinergic hypothesis of dys-
thymic disorders [30] opioid peptides have been consid-
ered potential candidates for the development of novel
antidepressant treatment [31,32].
On clinical grounds, the efficacy of b-endorphins has
been assessed on non-addicted depressed patients [33].
Codeine has been evaluated as a possible therapeutic
agent in the treatment of involutional and senile depres-
sion [34]. More recently buprenorphine, thanks to its
partial agonist activity, bringing with it a reduced risk of
dependence and abuse, has turned out to offer an effec-
tive therapeutic strategy in depressed patients who are
unresponsive to, or intolerant of, conventional antide-
pressant agents [35-37].
Although opiates are known to produce euphoric
states, and spontaneous states of elation are associated
with high CNS levels of endorphins, a low incidence of
manic states has been reported among heroin addicts.
Methadone maintenance has been observed to achieve
major mood stabilization in bipolar I patients; this sup-
ports the idea that opioid agonists may display an anti-
manic effect [11,32,38]. The opiate antagonist naloxone
has likewise shown antimanic properties probably attri-
butable to its hypothesized negative influence on basal
mood, formulated on the basis of observations on
addicted or non-addicted patients [39-42].
With regard to anxiety disorders, opioid agents have
been reported to display antipanic effects [32]. Consis-
tently with these observations, naltrexone has been
shown to elicit anxiety and to induce panic attacks in
non-addicted as well as addicted patients [40].
Some authors have hypothesized a direct involvement
of opioid neuropeptides in the pathophysiology of psy-
chotic disorders [43]. The antipsychotic effectiveness of
opiate agonists [44] is supported by the fact that metha-
done maintenance is responsible for the prevention of
psychotic relapses in individuals with a history of psy-
chotic episodes. In the same subjects, the gradual elimi-
nation of methadone was followed by psychotic relapses
[45]. The use of methadone has been proposed as a
treatment in cases of schizophrenia that have turned out
to be resistant to traditional medications, and again in
cases of the early development of dyskinesias [46].
Going forward when combined with methadone, low
dosages of antipsychotics, such as chlorpromazine, flufe-
nazine and haloperidol are needed to control psychotic
symptoms [47-49]. This therapeutic suggestion is in line
with the antidopaminergic activity of methadone, as
documented by the increase in serum prolactin after its
administration [50]. In line with these observations, our
heroin-dependent patients with prominently psycho-
pathological sensitivity-psychoticism characteristics
showed a better level of retention in treatment when
treated with methadone.
A series of studies indicates that opiate agonists are
likely to be effective in controlling aggressive behavior
in opiate-addicted patients, as confirmed by the fall in
levels of aggressiveness which follows adequate metha-
done treatment [51,52]. Moreover, aggressive symptoms
are among the features that may be found in the habit
of applying a self-medication theory [53]. In this study
buprenorphine showed better results than methadone in
patients with prominently aggressive characteristics (in
the violence-suicide dominant group).
Conclusions
The observations reported in the literature and the
results of this study suggest that opioid agonists should
be reconsidered, as they not only possess an anticraving
activity but are also able to act as psychotropic instru-
ments in treating mental illness, with special reference
to mood, anxiety and psychotic syndromes. In particular,
methadone seems to be more effective on sensitivity-
psychoticism aspects, whereas buprenorphine seems to
be more effective on aggressive behavior (violence-sui-
cide). As a result, some dual diagnosis patients may ben-
efit from a treatment (methadone or buprenorphine)
that not only targets their addictive problem but is also
effective on their mental disorder.
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